Publications by authors named "K Kibata"
Article Synopsis
- The study investigates the combined efficacy of afatinib, an EGFR-tyrosine kinase inhibitor, and bevacizumab, a VEGF inhibitor, in patients with EGFR-mutant non-small cell lung cancer who have become resistant to osimertinib.
- Out of 28 enrolled patients, the combination treatment resulted in a 17.9% response rate and an overall disease control rate of 78.6%, with a median duration of response of 9 months.
- The analysis of rebiopsied samples identified various resistance mechanisms, revealing that certain mutations (like C797S and uncommon EGFR mutations) were associated with better responses, while patients with T790M
Background: Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efficacy of combination treatment with osimertinib and afatinib for patients with acquired resistance to osimertinib.
Methods: This open-label phase I study was a feasibility study of the combination of afatinib and osimertinib for patients with advanced EGFR-positive NSCLC who had progressive disease after receiving osimertinib.
Thoracic SMARCA4-deficient undifferentiated tumors are a new type of neoplasm that commonly occur in the mediastinum, progress rapidly, and show a poorer prognosis. We report a case of thoracic SMARCA4-deficient undifferentiated tumor in the right thoracic cavity in a patient with a history of heavy smoking and presenting with respiratory distress and hemoptysis. Imaging showed pleural effusion and thickening.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors like nivolumab improve survival rates for patients with non-small cell lung cancer (NSCLC), but current methods to predict treatment response are not completely reliable.
- A study conducted at Kansai Medical University Hospital examined RNA gene expression to differentiate between responders and non-responders to nivolumab therapy among NSCLC patients.
- Results indicated specific gene expressions (MAGE-A4, BBC3, OTOA for adenocarcinoma; DAB2, HLA-DPB1, CDH2 for squamous cell carcinoma) that could help predict treatment effectiveness, highlighting the need for tailored approaches based on cancer type.
Background: Salvage surgery is an effective therapeutic option for patients experiencing relapses after chemoradiotherapy for advanced-stage lung cancer or after high-dose radiotherapy for early-stage lung cancer. We report a case involving an emergent salvage surgery for a patient with massive hemoptysis who developed lung cancer recurrence after undergoing proton beam therapy 7 years prior to presentation.
Case Presentation: A 70-year-old male patient was emergently admitted due to massive hemoptysis.